Sugi Predict

Sugi Predict / Compounds / SCHEMBL924522

SCHEMBL924522

SCHEMBL924522

N=C(N)N/N=C/c1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.60
▸ KMT2A Q03164 3/20 0.60
▸ KDM4E B2RXH2 1/20 0.52
▸ RAB9A P51151 3/20 0.51
▸ NPC1 O15118 2/20 0.51
▸ ALDH1A1 P00352 1/20 0.51
▸ LMNA P02545 1/20 0.51
▸ CYP1A2 P05177 1/20 0.51
▸ CYP3A4 P08684 1/20 0.51
▸ CYP2C9 P11712 1/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ POLB P06746 1/20 0.50
▸ NOX1 Q9Y5S8 1/20 0.48
▸ G6PD P11413 1/20 0.47
▸ GRIN2D O15399 2/20 0.47
▸ GRIN3B O60391 2/20 0.47
▸ GRIN1 Q05586 2/20 0.47
▸ GRIN2A Q12879 2/20 0.47
▸ GRIN2B Q13224 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL914606 1.00 MEN1 (0.60) MEN1KMT2AKDM4ERAB9ANPC1
Hydrochloric Acid SCHEMBL9618642 0.98 MEN1 (0.58) MEN1KMT2AKDM4ERAB9ANPC1
Hydrochloric Acid SCHEMBL9618643 0.98 MEN1 (0.58) MEN1KMT2AKDM4ERAB9ANPC1
Acetic Acid SCHEMBL917458 0.91 MEN1 (0.61) MEN1KMT2ARAB9ANPC1ALDH1A1
Acetic Acid SCHEMBL917457 0.91 MEN1 (0.61) MEN1KMT2ARAB9ANPC1ALDH1A1
SCHEMBL10054978 0.90 KDM4E (0.63) MEN1KMT2AKDM4ERAB9AALDH1A1
SCHEMBL7743144 0.89 RAB9A (0.55) MEN1KMT2AKDM4ERAB9ANPC1
SCHEMBL7743143 0.89 RAB9A (0.55) MEN1KMT2AKDM4ERAB9ANPC1
Nitric Acid SCHEMBL5575095 0.88 MEN1 (0.53) MEN1KMT2AKDM4ERAB9ANPC1
Nitric Acid SCHEMBL5575099 0.88 MEN1 (0.53) MEN1KMT2AKDM4ERAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1576093-A4 3-DEOXYGLUCOSONE AND SKIN DYNAMIS THERAPEUTICS INC (US) 2009-07-08 — — EP claimed
US-20070065443-A1 Fructoseamine 3 kinase and the formation of collagen and elastin DYNAMIS THERAPEUTICS, INC. 2007-03-22 — — US claimed
EP-1753861-A2 FRUCTOSEAMINE 3 KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN Dynamis Therapeutics, Inc. (US) 2007-02-21 — — EP claimed
EP-1576093-A2 3-DEOXYGLUCOSONE AND SKIN Dynamis Therapeutics, Inc. (US) 2005-09-21 — — EP claimed
WO-2005079463-A2 FRUCTOSEAMINE 3 KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN DYNAMIS THERAPEUTICS, INC. (US) 2005-09-01 — — WO claimed
US-20050159383-A1 Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) DYNAMIS THERAPEUTICS, INC. 2005-07-21 — — US claimed
US-20030219440-A1 3-deoxyglucosone and skin DYNAMIS THERAPEUTICS, INC. 2003-11-27 — — US claimed
WO-2003089601-A2 3-DEOXYGLUCOSONE AND SKIN DYNAMIS THERAPEUTICS, INC. (US) 2003-10-30 — — WO claimed
WO-2001025192-A1 GUANIDINE DERIVATIVES AND THEIR USE IN THE PRODUCTION OF A MEDICAMENT FOR BLOCKING XANTHINE OXIDASE/DEHYDROGENASE MELACURE THERAPEUTICS AB (SE) 2001-04-12 — — WO claimed
US-4310541-A WITH A BIS(BENZYLIDENEAMINO)GUANIDINE MERCK & CO., INC. (US) 1982-01-12 — — US claimed
US-11337941-B2 Inhibitors and their uses UNITED KINGDOM RESEARCH AND INNOVATION (GB) 2022-05-24 — — US disclosed
US-11331286-B2 Inhibitors and their uses UNITED KINGDOM RESEARCH AND INNOVATION (GB) 2022-05-17 — — US disclosed
US-20220015367-A1 SELF-ASSEMBLED ACTIVE AGENTS METHODS PRODUCTS PBC 2022-01-20 — — US disclosed
US-11154519-B2 Inhibitors and their uses UNITED KINGDOM RESEARCH AND INNOVATION (GB) 2021-10-26 — — US disclosed
CN-107787321-B Novel5-HT2Antagonists 安娜玛有限公司 2021-10-01 — — CN disclosed
US-4107326-A ANTIHYPERTENSIVE AGENTS, DIURETICS AMERICAN CYANAMID COMPANY (US) 1978-08-15 — — US disclosed
US-4060640-A O-HALOBENZYLIDENEAMINO GUANIDINES, CNS DEPRESSANT SHELL OIL COMPANY (US) 1977-11-29 — — US disclosed
US-4006249-A Systemic treatment of psoriasis AMERICAN HOME PRODUCTS CORPORATION (US) 1977-02-01 — — US disclosed
US-3975533-A O-HALOBENZYLIDENEAMINOGUANIDINES, ANTIDEPRESSANT SHELL OIL COMPANY (US) 1976-08-17 — — US disclosed
US-3941825-A ANTIPROTOZOA INTERMEDIATES AMERICAN CYANAMID COMPANY (US) 1976-03-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070065443-A1 Fructoseamine 3 kinase and the formation of collagen and elastin FN3K, PDXK, COLGALT1 MEN1 1069/4885KMT2A 2468/4885KDM4E 1956/4885
US-11154519-B2 Inhibitors and their uses PPP1R1B, PPP5C, PPP1R15A MEN1 2415/4885KMT2A 3446/4885KDM4E 1965/4885
US-11331286-B2 Inhibitors and their uses PPP1R1B, PPP5C, PPP1R15A MEN1 2415/4885KMT2A 3446/4885KDM4E 1965/4885
US-20030219440-A1 3-deoxyglucosone and skin DPM1, G6PD, UGGT1 MEN1 1559/4885KMT2A 3495/4885KDM4E 897/4885
US-20050159383-A1 Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) AGER, GLA, GALE MEN1 3627/4885KMT2A 2646/4885KDM4E 441/4885
US-20220015367-A1 SELF-ASSEMBLED ACTIVE AGENTS PCNA, POLM, MUS81 MEN1 2860/4885KMT2A 1623/4885KDM4E 3334/4885
US-11337941-B2 Inhibitors and their uses PPP1R1B, PPP5C, PPP1R15A MEN1 2415/4885KMT2A 3446/4885KDM4E 1965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.